Inactivation of the pseudomonas-derived cephalosporinase-3 (PDC-3) by Relebactam

33Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas-derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa. In this investigation, we show that relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates PDC-3, with a k2/K of 41,400 M-1 s-1 and a koff of 0.00095 s-1. Relebactam restored susceptibility to imipenem in 62% of multidrug-resistant P. aeruginosa clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin against P. aeruginosa.

Cite

CITATION STYLE

APA

Barnes, M. D., Bethel, C. R., Alsop, J., Becka, S. A., Rutter, J. D., Papp-Wallace, K. M., & Bonomoa, R. A. (2018). Inactivation of the pseudomonas-derived cephalosporinase-3 (PDC-3) by Relebactam. Antimicrobial Agents and Chemotherapy, 62(5). https://doi.org/10.1128/AAC.02406-17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free